MarketPulse

neurological disorders

5 articles
The Motley FoolThe Motley Fool··Jonathan Ponciano

Xenon Pharma Soars 55% on Trial Success Despite Insider Share Sale

Xenon Pharmaceuticals' CMO sold $78K in shares via routine vesting, as stock surges 55% following positive Phase 3 trial results and $750M capital raise.
XENEbiotechcapital raise
The Motley FoolThe Motley Fool··Jonathan Ponciano

Biotech Darling $PRAX Soars 700% as Top Fund Trims Position Yet Doubles Down

Cormorant Asset Management sold $PRAX shares for $9.3M in Q4, yet position surged $227M in value. Stock remains fund's largest holding at $280M.
EYPTPRAXABVXFDA approvalbiotech
GlobeNewswire Inc.GlobeNewswire Inc.··Sns Insider

Neurorehab Market Set to Triple to $6.96B by 2035 on Neurological Disease Surge

Global neurorehabilitation market projected to grow from $2.46B in 2025 to $6.96B by 2035, driven by rising neurological disorders and technological advances.
MDTEKSOBNKLhealthcare technologymarket growth
GlobeNewswire Inc.GlobeNewswire Inc.··Delveinsight

Neuromodulation Device Market to Double by 2032 Amid Rising Neurological Disease Burden

Neuromodulation device market expected to double to $16.1 billion by 2032, driven by rising neurological diseases, technological advances, and regulatory support.
MDTBSXABTLIVNFDA approvalmarket growth
GlobeNewswire Inc.GlobeNewswire Inc.··Sns Insider

Brain-Computer Interface Market Set for Rapid Expansion Through 2035

Brain-computer interface market projected to grow from $3.07B to $13.32B by 2035, driven by technological advances and neurological disorder prevalence.
MDTmarket growthmedical technology